Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Florida Cancer Specialists & Research Institute (fcs)
Sarasota, Florida, United States
- Dana Farber Cancer Instiyute
Boston, Massachusetts, United States
- Stephenson Cancer Center (university of Oklahoma)
Oklahoma City, Oklahoma, United States
- Sarah Cannon Research Institute at Tennessee Oncology
Nashville, Tennessee, United States
- Mary Crowley Cancer Research Centers
Dallas, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2016
- Primary completion
- 28 Aug 2018
- Completion
- 28 Dec 2018
- Last update posted
- 30 Apr 2019
- Registered enrollment
- 98
- Registry id
- NCT02943317
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.